(MedPage Today) — The GIP/GLP-1 dual agonist tirzepatide (Mounjaro) showed cardiovascular protective benefits over dulaglutide (Trulicity) in the phase III SURPASS-CVOT trial of diabetes patients with heart disease, Lilly announced.
The FDA approved…
Source link : https://www.medpagetoday.com/cardiology/generalcardiology/116835
Author :
Publish date : 2025-08-05 17:02:00
Copyright for syndicated content belongs to the linked Source.
